the Reason 2 O O
U.S. Reason 2 ScientificAuthority O
Food Reason 2 ScientificAuthority O
and Reason 2 ScientificAuthority O
Drug Reason 2 ScientificAuthority O
Administration Reason 2 ScientificAuthority O
and Reason 2 O O
Centers Reason 2 ScientificAuthority O
for Reason 2 ScientificAuthority O
Disease Reason 2 ScientificAuthority O
Control Reason 2 ScientificAuthority O
and Reason 2 ScientificAuthority O
Prevention Reason 2 ScientificAuthority O
announced Reason 2 O O
they Reason 2 O O
are Reason 2 O O
[recommending Reason 2 O O
a Reason 2 O O
pause](https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine) Reason 2 O O
in Reason 2 O O
use Reason 2 O O
of Reason 2 O O
the Reason 2 O O
Johnson Reason 2 O O
& Reason 2 O O
Johnson Reason 2 O O
COVID-19 Reason 2 O O
vaccine Reason 2 O O
in Reason 2 O O
the Reason 2 O O
U.S. Reason 2 O O
while Reason 2 O O
scientists Reason 2 O O
investigate Reason 2 O O
a Reason 2 O O
possible Reason 2 O O
but Reason 2 O O
rare Reason 2 O O
link Reason 2 O O
between Reason 2 O O
the Reason 2 O O
vaccine Reason 2 O O
and Reason 2 O O
a Reason 2 O O
blood Reason 2 O O
clot Reason 2 O O
combined Reason 2 O O
with Reason 2 O O
a Reason 2 O O
low Reason 2 O O
platelet Reason 2 O O
count. Reason 2 O O
Six Reason 3 O O
individuals Reason 3 O O
out Reason 3 O O
of Reason 3 O O
nearly Reason 3 O O
seven Reason 3 O O
million Reason 3 O O
people Reason 3 O O
who Reason 3 O O
have Reason 3 O O
gotten Reason 3 O O
this Reason 3 O O
vaccine Reason 3 O O
in Reason 3 O O
the Reason 3 O O
U.S. Reason 3 O O
developed Reason 3 O O
the Reason 3 O O
condition, Reason 3 O O
which Reason 3 O O
appears Reason 3 O O
to Reason 3 O O
be Reason 3 O O
similar Reason 3 O O
to Reason 3 O O
one Reason 3 O O
seen Reason 3 O O
in Reason 3 O O
just Reason 3 O O
a Reason 3 O O
few Reason 3 O O
cases Reason 3 O O
among Reason 3 O O
people Reason 3 O O
who Reason 3 O O
received Reason 3 O O
the Reason 3 O O
AstraZeneca Reason 3 O O
vaccine Reason 3 O O
in Reason 3 O O
Europe, Reason 3 O O
which Reason 3 O O
is Reason 3 O O
described Reason 3 O O
in Reason 3 O O
the Reason 3 O O
story Reason 3 O O
below. Reason 3 O O
Both O O O O
vaccines O O O O
consist O O O O
of O O O O
an O O O O
adenovirus O O O O
vector O O O O
that O O O O
delivers O O O O
DNA O O O O
for O O O O
the O O O O
novel O O O O
coronavirus's O O O O
spike O O O O
protein. O O O O
U.S. Reason 3 O O
officials Reason 3 O O
emphasized Reason 3 O O
that Reason 3 O O
these Reason 3 O O
phenomena Reason 3 O O
are Reason 3 O O
extremely Reason 3 O O
rare Reason 3 O O
and Reason 3 O O
that Reason 3 O O
they Reason 3 O O
were Reason 3 O O
pausing Reason 3 O O
the Reason 3 O O
Johnson Reason 3 O O
& Reason 3 O O
Johnson Reason 3 O O
vaccine's Reason 3 O O
use Reason 3 O O
"out Reason 3 O O
of Reason 3 O O
an Reason 3 O O
abundance Reason 3 O O
of Reason 3 O O
caution." Reason 3 O O
The Reason 4 O O
other Reason 4 O O
vaccines Reason 4 O O
authorized Reason 4 O O
for Reason 4 O O
use Reason 4 O O
in Reason 4 O O
the Reason 4 O O
country, Reason 4 O O
made Reason 4 O O
by Reason 4 O O
Pfizer Reason 4 O O
and Reason 4 O O
Moderna, Reason 4 O O
remain Reason 4 O O
safe Reason 4 O O
and Reason 4 O O
effective. Reason 4 O O
The O O O O
very O O O O
rare O O O O
occurrence O O O O
of O O O O
a O O O O
mysterious O O O O
blood-clotting O O O O
disorder O O O O
among O O O O
some O O O O
recipients O O O O
of O O O O
the O O O O
Oxford-AstraZeneca O O O O
COVID-19 O O O O
vaccine O O O O
has O O O O
researchers O O O O
scrambling O O O O
to O O O O
uncover O O O O
whether O O O O
and O O O O
how O O O O
the O O O O
inoculation O O O O
could O O O O
trigger O O O O
such O O O O
an O O O O
unusual O O O O
reaction. O O O O
After Reason 2 O O
weeks Reason 2 O O
of Reason 2 O O
investigation, Reason 2 O O
the Reason 2 O O
European Reason 2 ScientificAuthority O
Medicines Reason 2 ScientificAuthority O
Agency Reason 2 ScientificAuthority O
(EMA) Reason 2 ScientificAuthority O
announced Reason 2 O O
on Reason 2 O O
7 Reason 2 O O
April Reason 2 O O
that Reason 2 O O
there Reason 2 O O
is Reason 2 O O
a Reason 2 O O
possible Reason 2 O O
link Reason 2 O O
between Reason 2 O O
the Reason 2 O O
clots Reason 2 O O
and Reason 2 O O
the Reason 2 O O
vaccine. Reason 2 O O
Even O O O O
so, O O O O
the O O O O
clotting O O O O
disorder—described O O O O
today O O O O
in O O O O
two O O O O
reports O O O O
in O O O O
The O O ScientificAuthority O
New O O ScientificAuthority O
England O O ScientificAuthority O
Journal O O ScientificAuthority O
of O O ScientificAuthority O
Medicine— O O ScientificAuthority O
is O O O O
so O O O O
uncommon O O O O
that O O O O
the O O O O
benefits O O O O
of O O O O
the O O O O
vaccine O O O O
still O O O O
outweigh O O O O
its O O O O
risks, O O O O
EMA O O O O
executive O O O O
director O O O O
Emer O O ScientificAuthority O
Cooke O O ScientificAuthority O
told O O O O
reporters. O O O O
"These Reason 4 O O
are Reason 4 O O
very Reason 4 O O
rare Reason 4 O O
side Reason 4 O O
effects," Reason 4 O O
she Reason 4 O O
said. Reason 4 O O
"The Reason 4 O O
risk Reason 4 O O
of Reason 4 O O
mortality Reason 4 O O
from Reason 4 O O
COVID Reason 4 O O
is Reason 4 O O
much Reason 4 O O
greater Reason 4 O O
than Reason 4 O O
the Reason 4 O O
risk Reason 4 O O
of Reason 4 O O
mortality Reason 4 O O
from Reason 4 O O
these Reason 4 O O
side Reason 4 O O
effects." Reason 4 O O
But O O O O
the O O O O
finding O O O O
leaves O O O O
researchers O O O O
wrestling O O O O
with O O O O
a O O O O
medical O O O O
mystery: O O O O
why O O O O
would O O O O
a O O O O
vaccine O O O O
trigger O O O O
such O O O O
an O O O O
unusual O O O O
condition? O O O O
"Of O O O O
course, O O O O
there O O O O
are O O O O
hypotheses: O O O O
maybe O O O O
it's O O O O
something O O O O
with O O O O
the O O O O
vector, O O O O
maybe O O O O
it's O O O O
an O O O O
additive O O O O
in O O O O
the O O O O
vaccine, O O O O
maybe O O O O
it's O O O O
something O O O O
in O O O O
the O O O O
production O O O O
process O O O O
... O O O O
I O O O O
don't O O O O
know," O O O O
says O O O O
Sabine O O ScientificAuthority O
Eichinger, O O ScientificAuthority O
a O O O O
haematologist O O O O
at O O O O
the O O O O
Medical O O ScientificAuthority O
University O O ScientificAuthority O
of O O ScientificAuthority O
Vienna. O O ScientificAuthority O
"It O O O O
could O O O O
be O O O O
any O O O O
of O O O O
these O O O O
things." O O O O
Unusual O O O O
locations O O O O
Eichinger O O O O
was O O O O
among O O O O
the O O O O
first O O O O
to O O O O
notice O O O O
the O O O O
clotting O O O O
disorder, O O O O
a O O O O
strange O O O O
combination O O O O
of O O O O
blood O O O O
clots—which O O O O
can O O O O
be O O O O
dangerous, O O O O
and O O O O
potentially O O O O
fatal, O O O O
if O O O O
they O O O O
block O O O O
blood O O O O
flow O O O O
to O O O O
the O O O O
brain O O O O
or O O O O
lungs—and O O O O
a O O O O
counter-intuitive O O O O
deficiency O O O O
of O O O O
cell O O O O
fragments O O O O
called O O O O
platelets O O O O
that O O O O
promote O O O O
clotting. O O O O
The O O O O
clots O O O O
also O O O O
appeared O O O O
in O O O O
unusual O O O O
parts O O O O
of O O O O
the O O O O
body, O O O O
such O O O O
as O O O O
the O O O O
brain O O O O
and O O O O
abdomen, O O O O
rather O O O O
than O O O O
in O O O O
the O O O O
legs, O O O O
where O O O O
most O O O O
deep-vein O O O O
blood O O O O
clots O O O O
form. O O O O
This O O O O
rang O O O O
alarm O O O O
bells O O O O
for O O O O
Eichinger, O O O O
who O O O O
had O O O O
previously O O O O
encountered O O O O
a O O O O
similar O O O O
phenomenon O O O O
in O O O O
a O O O O
few O O O O
people O O O O
who O O O O
had O O O O
been O O O O
treated O O O O
with O O O O
the O O O O
blood-thinning O O O O
drug O O O O
heparin. O O O O
Heparin O O O O
is O O O O
normally O O O O
used O O O O
to O O O O
prevent O O O O
clotting, O O O O
but O O O O
in O O O O
very O O O O
rare O O O O
cases O O O O
can O O O O
trigger O O O O
a O O O O
syndrome O O O O
called O O O O
heparin-induced O O O O
thrombocytopenia O O O O
(HIT), O O O O
which O O O O
causes O O O O
blood O O O O
clots O O O O
together O O O O
with O O O O
low O O O O
platelet O O O O
levels. O O O O
By Reason 2 O O
22 Reason 2 O O
March, Reason 2 O O
the Reason 2 O O
EMA Reason 2 O O
had Reason 2 O O
assembled Reason 2 O O
86 Reason 2 O O
reports Reason 2 O O
of Reason 2 O O
people Reason 2 O O
who Reason 2 O O
had Reason 2 O O
experienced Reason 2 O O
blood Reason 2 O O
clots Reason 2 O O
in Reason 2 O O
the Reason 2 O O
brain Reason 2 O O
or Reason 2 O O
abdomen Reason 2 O O
within Reason 2 O O
two Reason 2 O O
weeks Reason 2 O O
of Reason 2 O O
receiving Reason 2 O O
a Reason 2 O O
dose Reason 2 O O
of Reason 2 O O
the Reason 2 O O
Oxford-AstraZeneca Reason 2 O O
vaccine, Reason 2 O O
developed Reason 2 O O
in Reason 2 O O
Britain Reason 2 O O
by Reason 2 O O
AstraZeneca Reason 2 O O
in Reason 2 O O
Cambridge Reason 2 O O
and Reason 2 O O
the Reason 2 O O
University Reason 2 O O
of Reason 2 O O
Oxford. Reason 2 O O
Some O O O O
of O O O O
these O O O O
cases O O O O
have O O O O
been O O O O
confirmed O O O O
to O O O O
bear O O O O
the O O O O
hallmarks O O O O
of O O O O
HIT, O O O O
even O O O O
though O O O O
these O O O O
people O O O O
had O O O O
not O O O O
received O O O O
heparin. O O O O
Risk O O O O
factors O O O O
The O O O O
EMA O O O O
is O O O O
asking O O O O
AstraZeneca O O O O
to O O O O
conduct O O O O
a O O O O
number O O O O
of O O O O
investigations, O O O O
including O O O O
laboratory O O O O
studies O O O O
to O O O O
determine O O O O
the O O O O
effect O O O O
of O O O O
the O O O O
vaccine O O O O
on O O O O
blood O O O O
clotting, O O O O
and O O O O
evaluations O O O O
of O O O O
data O O O O
from O O O O
clinical O O O O
trials, O O O O
to O O O O
try O O O O
to O O O O
glean O O O O
any O O O O
further O O O O
information O O O O
about O O O O
risk O O O O
factors. O O O O
Although O O O O
there O O O O
are O O O O
reports O O O O
that O O O O
the O O O O
syndrome O O O O
is O O O O
seen O O O O
more O O O O
often O O O O
in O O O O
women O O O O
than O O O O
in O O O O
men, O O O O
particularly O O O O
those O O O O
aged O O O O
under O O O O
60, O O O O
the O O O O
EMA O O O O
was O O O O
unable O O O O
to O O O O
conclude O O O O
that O O O O
women O O O O
are O O O O
at O O O O
higher O O O O
risk. O O O O
Many O O O O
countries O O O O
prioritized O O O O
health-care O O O O
workers O O O O
to O O O O
receive O O O O
the O O O O
inoculations, O O O O
and O O O O
women O O O O
comprise O O O O
a O O O O
larger O O O O
segment O O O O
of O O O O
this O O O O
workforce. O O O O
The O O O O
EMA O O O O
is O O O O
also O O O O
supporting O O O O
studies O O O O
by O O O O
two O O O O
academic O O O O
consortia O O O O
centered O O O O
in O O O O
the O O O O
Netherlands, O O O O
one O O O O
led O O O O
by O O O O
Erasmus O O ScientificAuthority O
University O O ScientificAuthority O
Medical O O ScientificAuthority O
Center O O ScientificAuthority O
in O O ScientificAuthority O
Rotterdam O O ScientificAuthority O
and O O O O
the O O O O
other O O O O
by O O O O
investigators O O O O
at O O O O
Utrecht O O ScientificAuthority O
University O O ScientificAuthority O
and O O O O
the O O O O
University O O ScientificAuthority O
Medical O O ScientificAuthority O
Center O O ScientificAuthority O
Utrecht. O O ScientificAuthority O
Their O O O O
project O O O O
list O O O O
is O O O O
ambitious. O O O O
The O O O O
consortium, O O O O
co-chaired O O O O
by O O O O
virologist O O O O
Eric O O O O
C. O O O O
M. O O O O
van O O O O
Gorp O O O O
at O O O O
Erasmus, O O O O
consists O O O O
of O O O O
22 O O O O
hospitals O O O O
that O O O O
have O O O O
been O O O O
working O O O O
together O O O O
to O O O O
study O O O O
the O O O O
effects O O O O
of O O O O
coronavirus O O O O
on O O O O
blood O O O O
coagulation. O O O O
The O O O O
team O O O O
will O O O O
look O O O O
for O O O O
potential O O O O
cases O O O O
of O O O O
HIT O O O O
among O O O O
cases O O O O
of O O O O
blood O O O O
clots O O O O
following O O O O
vaccination O O O O
with O O O O
the O O O O
Oxford-AstraZeneca O O O O
vaccine O O O O
and O O O O
other O O O O
COVID-19 O O O O
vaccines. O O O O
It O O O O
will O O O O
also O O O O
conduct O O O O
lab O O O O
studies O O O O
to O O O O
look O O O O
for O O O O
signs O O O O
that O O O O
the O O O O
already-small O O O O
risk O O O O
could O O O O
be O O O O
cut O O O O
even O O O O
further O O O O
by O O O O
reducing O O O O
the O O O O
amount O O O O
of O O O O
vaccine O O O O
administered O O O O
in O O O O
each O O O O
dose. O O O O
The O O O O
EMA O O O O
expects O O O O
to O O O O
obtain O O O O
some O O O O
results O O O O
from O O O O
the O O O O
projects O O O O
within O O O O
the O O O O
next O O O O
two O O O O
months, O O O O
said O O O O
Peter O O O O
Arlett, O O O O
head O O O O
of O O O O
the O O O O
agency's O O O O
Data O O O O
Analytics O O O O
and O O O O
Methods O O O O
task O O O O
force. O O O O
The O O O O
team O O O O
will O O O O
also O O O O
try O O O O
to O O O O
tease O O O O
apart O O O O
whether O O O O
this O O O O
problem O O O O
is O O O O
restricted O O O O
to O O O O
certain O O O O
populations. O O O O
"What O O O O
we O O O O
find O O O O
in O O O O
Western O O O O
Europe O O O O
will O O O O
not O O O O
automatically O O O O
be O O O O
true O O O O
in O O O O
South O O O O
America O O O O
or O O O O
other O O O O
populations," O O O O
says O O O O
van O O O O
Gorp. O O O O
"This Reason 2 O O
is Reason 2 O O
a Reason 2 O O
worldwide Reason 2 O O
problem; Reason 2 O O
everyone Reason 2 O O
is Reason 2 O O
concerned." Reason 2 O O
And, Reason 2 O O
critically, Reason 2 O O
van Reason 2 O O
Gorp Reason 2 O O
and Reason 2 O O
his Reason 2 O O
colleagues Reason 2 O O
will Reason 2 O O
try Reason 2 O O
to Reason 2 O O
further Reason 2 O O
evaluate Reason 2 O O
whether Reason 2 O O
the Reason 2 O O
"probable" Reason 2 O O
association Reason 2 O O
between Reason 2 O O
the Reason 2 O O
vaccine Reason 2 O O
and Reason 2 O O
the Reason 2 O O
syndrome Reason 2 O O
is Reason 2 O O
real. Reason 2 O O
It O O O O
is O O O O
notoriously O O O O
[difficult O O O O
to O O O O
confirm](https://www.nature.com/articles/d41586-021-00880-9) O O O O
whether O O O O
a O O O O
suspected O O O O
rare O O O O
effect O O O O
of O O O O
a O O O O
vaccine O O O O
is O O O O
truly O O O O
linked O O O O
to O O O O
the O O O O
vaccine—particularly O O O O
when O O O O
it O O O O
is O O O O
a O O O O
vaccine O O O O
that O O O O
has O O O O
been O O O O
used O O O O
in O O O O
tens O O O O
of O O O O
millions O O O O
of O O O O
people. O O O O
"Somebody Reason 4 O O
who Reason 4 O O
gets Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
could Reason 4 O O
have Reason 4 O O
a Reason 4 O O
stroke Reason 4 O O
or Reason 4 O O
a Reason 4 O O
heart Reason 4 O O
attack Reason 4 O O
a Reason 4 O O
week Reason 4 O O
later Reason 4 O O
because Reason 4 O O
they Reason 4 O O
were Reason 4 O O
already Reason 4 O O
going Reason 4 O O
to Reason 4 O O
have Reason 4 O O
a Reason 4 O O
stroke Reason 4 O O
or Reason 4 O O
a Reason 4 O O
heart Reason 4 O O
attack," Reason 4 O O
says O O O O
cardiologist O O O O
Behnood O O ScientificAuthority O
Bikdeli O O ScientificAuthority O
at O O O O
Brigham O O ScientificAuthority O
and O O ScientificAuthority O
Women's O O ScientificAuthority O
Hospital O O ScientificAuthority O
in O O ScientificAuthority O
Boston, O O ScientificAuthority O
Massachusetts O O O O
